BioMedNewsBreaks — Brain Scientific Inc. (BRSF) Announces Acquisition Agreement

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has entered into a definitive merger agreement to acquire Piezo Motion Corp., a leading innovator of high-precision piezoelectric motion technology. According to the announcement, the merger is designed to expand the market reach of both companies along with their ability to deliver innovative technologies to high-growth markets. Both companies have built impressive teams of scientists, engineers and executives with invaluable expertise in developing and commercializing disruptive technologies, and the acquisition will result in a single company with vast machine learning background and astute ability to address demands in the market. Currently, BRSF’s neurology products create massive amounts of data health care providers can use in determining best treatments and protocols; the new company will utilize Piezo Motion’s technology to enhance these products. “We are excited for the future that the merger with Piezo Motion is expected to bring,” said Brain Scientific founder Dr. Baruch Goldstein in the press release. “Together, we plan to achieve rapid expansion while delivering and developing the new generation of MedTech solutions for the brain diagnostics market, including innovative products for long-term monitoring and brain e-tattoo. This combination offers a significant opportunity to be part of a company well positioned for growth. We look forward to uniting with Piezo Motion in what we expect will be an exciting new chapter ahead.”

To view the full press release, visit https://ibn.fm/KbPDO

About Brain Scientific Inc.

Brain Scientific is a commercial-stage health care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — NextPlat Corp. (NASDAQ: NXPL, NXPLW) to Announce Q3 2025 Financial Results on Nov. 13 

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology…

2 hours ago

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present Sapu003 Data at 2025 San Antonio Breast Cancer Symposium

Oncotelic Therapeutics (OTCQB: OTLC) a biopharmaceutical company advancing transformative cancer therapies through its PDAOAI platform…

3 days ago

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Schedules Third Quarter 2025 Conference Call for Nov. 13 

HeartBeam (NASDAQ: BEAT), a medical technology company transforming cardiac care through personalized insights, will hold…

4 days ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Nanomedicine Advances 

Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a NetworkNewsWire (“NNW”) editorial titled “Nanomedicine Innovations…

4 days ago

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL, NXPLW) Granted 180-Day Nasdaq Extension to Regain Minimum Bid Price Compliance

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology…

5 days ago

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Receives FDA Meeting Feedback Advancing AVERSA(TM) Fentanyl Toward 505(b)(2) NDA Submission 

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, today announced it has received…

6 days ago